Soligenix Shares Outstanding 2006-2021 | SNGX

Soligenix shares outstanding from 2006 to 2021. Shares outstanding can be defined as the number of shares held by shareholders (including insiders) assuming conversion of all convertible debt, securities, warrants and options. This metric excludes the company's treasury shares.
Soligenix Annual Shares Outstanding
(Millions of Shares)
2020 27
2019 19
2018 13
2017 6
2016 4
2015 3
2014 2
2013 2
2012 1
2011 1
2010 1
2009 1
2008 1
2007 0
2006 0
2005 0
Soligenix Quarterly Shares Outstanding
(Millions of Shares)
2021-06-30 40
2021-03-31 37
2020-12-31 27
2020-09-30 30
2020-06-30 27
2020-03-31 23
2019-12-31 19
2019-09-30 20
2019-06-30 18
2019-03-31 18
2018-12-31 13
2018-09-30 17
2018-06-30 9
2018-03-31 9
2017-12-31 6
2017-09-30 6
2017-06-30 6
2017-03-31 5
2016-12-31 4
2016-09-30 3
2016-06-30 3
2016-03-31 3
2015-12-31 3
2015-09-30 3
2015-06-30 3
2015-03-31 2
2014-12-31 2
2014-09-30 2
2014-06-30 2
2014-03-31 2
2013-12-31 2
2013-09-30 2
2013-06-30 1
2013-03-31 1
2012-12-31 1
2012-09-30 1
2012-06-30 1
2012-03-31 1
2011-12-31 1
2011-09-30 1
2011-06-30 1
2011-03-31 1
2010-12-31 1
2010-09-30 1
2010-06-30 1
2010-03-31 1
2009-12-31 1
2009-09-30 1
2009-06-30 1
2009-03-31 1
2008-12-31 1
2008-09-30 1
2008-06-30 1
2008-03-31 0
2007-12-31 0
2007-09-30 0
2007-06-30 0
2007-03-31 0
2006-12-31 0
2006-09-30 0
2006-06-30 0
2006-03-31 0
2005-12-31 0
2005-09-30 0
2005-06-30 0
2005-03-31 0
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.041B $0.002B
Soligenix, Inc. is a late-stage biopharmaceutical company focused on developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases where, as well as developing several biodefense vaccines and therapeutics. The Company operates in two reportable segments: BioTherapeutics and BioDefense. The BioTherapeutics business segment intends to develop orBec ? (oral beclomethasone dipropionate, or oral BDP) and other biotherapeutic products, including LPM TM Leuprolide. The BioDefense business segment intends to convert its ricin toxin vaccine and radiation injury programs from early stage development to advanced development and manufacturing. Soligenix, Inc, formerly known as DOR BioPharma, Inc, is headquartered in Princeton, New Jersey.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $128.460B 8.55
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.211B 20.68
Biohaven Pharmaceutical Holding (BHVN) United States $8.952B 0.00
Emergent Biosolutions (EBS) United States $2.717B 6.55
Arcus Biosciences (RCUS) United States $2.502B 0.00
Myovant Sciences (MYOV) United Kingdom $1.906B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.820B 0.00
Zymeworks (ZYME) Canada $1.088B 0.00
Ambrx Biopharma (AMAM) United States $0.513B 0.00
SQZ Biotechnologies (SQZ) United States $0.343B 0.00
Enzo Biochem (ENZ) United States $0.159B 15.57